Hoffmann-La Roche Inc.

Genentech, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-La Roche Ag

Joachim Moecks

Andreas Strauss

Lukas C Amler

Chin-Yu Lin

Astrid Heller

Armin Scherhag

Merrill Birkner

Verena Lutz

Otmar Herrgott, Legal Representative

Carol Ward

Ulrich Brennscheidt

Gerhard Zugmaier

Ildiko Amann-Zalan

Hans Ulrich Burger

Cesar Escrig

Frank Dougherty

Zuzana Hermann

Frank Ch Dougherty

Caesar Escrig

Ildiko Amann Zalan

Zuzana Herrmann

The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.

Predicting response to a HER inhibitor

The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.

Method for predicting the response to a treatment

The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.

Determination of responders to chemotherapy

Growing community of inventors

Mannheim, Germany

Joachim Moecks